4D Molecular Therapeutics, Inc. is a U.S. clinical-stage genetic medicines company developing adeno-associated virus (AAV) vector-based therapies designed for durable, disease-targeted expression after a single administration. Its near-term value is concentrated in 4D-150, an intravitreal gene therapy candidate for retinal vascular diseases (wet AMD and DME) that uses an R100 vector and a transgene cassette encoding aflibercept plus an inhibitory miRNA targeting VEGF-C. A second prioritized program, 4D-710, targets cystic fibrosis by delivering the CFTR transgene to the lung and is being advanced through the AEROW clinical trial. The company funds operations primarily through equity financings and, to a lesser extent, collaboration and license arrangements, including an APAC partnership with Otsuka for 4D-150.
−181,7 %
−164,4 %
+230 194,6 %
9.39
9.39
| % | |
|---|---|
| Ophthalmology gene therapy (4D-150) | 55% Intravitreal AAV gene therapy programs for retinal vascular diseases, led by 4D-150 in wet AMD and DME. |
| Pulmonology gene therapy (4D-710) | 20% Inhaled/lung-delivered genetic medicine programs focused on cystic fibrosis via CFTR transgene delivery. |
| Partnered/strategic alternative pipeline (4D-175, 4D-725, 4D-310) | 10% Non-prioritized clinical-stage programs intended for partnering or other strategic alternatives across GA, AATD, and Fabry cardiomyopathy. |
| Platform, IP and collaborations | 15% AAV capsid/vector platform capabilities and monetization via collaboration, licensing, milestones and royalties. |
As a pre-commercial biotechnology company, 4D Molecular Therapeutics’ near-term “customers” are primarily partners and...
License rights to develop/commercialize programs in specific territories (e.g., 4D-150 in APAC) in exchange for upfront cash, cost sharing, milestones and royalties.
Provide program-specific funding (e.g., CF Foundation support for AEROW Phase 2 start, redosing and Phase 3 readiness) to accelerate development and de-risk trials.
Would adopt 4D-150 if approved to reduce injection frequency and maintain vision outcomes with sustained intraocular anti-VEGF expression.
Would use 4D-710 if approved to address CFTR deficiency with durable lung expression and potential functional improvements.
4D Molecular Therapeutics is headquartered in the United States and runs clinical development across multiple...
Management’s stated direction is a pipeline prioritization that concentrates resources on 4D-150 (retinal vascular...
Late-stage data and regulatory submissions are the main catalysts for value creation and future commercialization outside partnered territories.
Demonstrating durable CFTR expression and clinical benefit would differentiate the program and support partnering or pivotal development.
Partnerships can extend runway and preserve optionality while focusing internal resources on the two priority programs.
The company has no approved products and is dependent on clinical trial success and regulatory approvals, making...
Business viability depends on successful completion of trials and approvals, which are uncertain and can materially change valuation and funding access.
Production problems can delay development/commercialization and limit supply, directly impacting timelines and costs.
Partner decisions and integration challenges can reduce expected milestones/royalties and slow regional commercialization.
MGTX · Biological Products, (No Diagnostic Substances)
MeiraGTx Holdings plc is a clinical-stage genetic medicines company developing adeno-associated virus (AAV) gene therapies for inherited retinal disease,…
CCCC · Biological Products, (No Diagnostic Substances)
MAZE · Biological Products, (No Diagnostic Substances)
MRKR · Pharmaceutical Preparations
VYGR · Biological Products, (No Diagnostic Substances)
OTLK · Biological Products, (No Diagnostic Substances)
: 11/08/2026